메뉴 건너뛰기




Volumn 60, Issue 2, 2008, Pages 215-221

Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment

Author keywords

Gefitinib; Gemcitabine; Nonsmall cell lung cancer; Paclitaxel; Platinum; Second line chemotherapy; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM;

EID: 42949152329     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.002     Document Type: Article
Times cited : (5)

References (32)
  • 1
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
    • (1995) BMJ , vol.311 , pp. 899-909
  • 2
    • 0028154069 scopus 로고
    • Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients
    • Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
    • (1994) J Clin Oncol , vol.12 , pp. 360-367
    • Le Chevalier, T.1    Brisgand, D.2    Douillard, J.Y.3    Pujol, J.L.4    Alberola, V.5    Monnier, A.6
  • 3
    • 0033950286 scopus 로고    scopus 로고
    • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial
    • Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18 (2000) 623-631
    • (2000) J Clin Oncol , vol.18 , pp. 623-631
    • Bonomi, P.1    Kim, K.2    Fairclough, D.3    Cella, D.4    Kugler, J.5    Rowinsky, E.6
  • 4
    • 0029098178 scopus 로고
    • Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis
    • Langer C.J., Leighton J.C., Comis R.L., O'Dwyer P.J., McAleer C.A., Bonjo C.A., et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13 (1995) 1860-1870
    • (1995) J Clin Oncol , vol.13 , pp. 1860-1870
    • Langer, C.J.1    Leighton, J.C.2    Comis, R.L.3    O'Dwyer, P.J.4    McAleer, C.A.5    Bonjo, C.A.6
  • 5
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer
    • The TAX 326 Study Group
    • Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al., The TAX 326 Study Group. Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 3016-3024
    • (2003) J Clin Oncol , vol.21 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    von Pawel, J.3    Pluzanska, A.4    Gorbounova, V.5    Kaukel, E.6
  • 6
    • 0032701095 scopus 로고    scopus 로고
    • Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project
    • Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 17 (1999) 3522-3530
    • (1999) J Clin Oncol , vol.17 , pp. 3522-3530
    • Crino, L.1    Scagliotti, G.V.2    Ricci, S.3    De Marinis, F.4    Rinaldi, M.5    Gridelli, C.6
  • 7
    • 0041912766 scopus 로고    scopus 로고
    • Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
    • Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
    • (2003) J Clin Oncol , vol.21 , pp. 3025-3034
    • Gridelli, C.1    Gallo, C.2    Shepherd, F.A.3    Illiano, A.4    Piantedosi, F.5    Robbiati, S.F.6
  • 8
    • 0028033227 scopus 로고
    • Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study
    • Anderson H., Lund B., Bach F., Thatcher N., Walling J., and Hansen H.H. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12 (1994) 1821-1826
    • (1994) J Clin Oncol , vol.12 , pp. 1821-1826
    • Anderson, H.1    Lund, B.2    Bach, F.3    Thatcher, N.4    Walling, J.5    Hansen, H.H.6
  • 10
    • 0041464768 scopus 로고    scopus 로고
    • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer
    • Le Chevalier T. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer. Semin Oncol 4 Suppl 10 (2003) 37-44
    • (2003) Semin Oncol , vol.4 , Issue.SUPPL. 10 , pp. 37-44
    • Le Chevalier, T.1
  • 11
    • 0027999966 scopus 로고
    • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion
    • Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., Gianni L., Myles J., van der Burg M.E., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12 (1994) 2654-2666
    • (1994) J Clin Oncol , vol.12 , pp. 2654-2666
    • Eisenhauer, E.A.1    ten Bokkel Huinink, W.W.2    Swenerton, K.D.3    Gianni, L.4    Myles, J.5    van der Burg, M.E.6
  • 12
    • 0035670904 scopus 로고    scopus 로고
    • A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer
    • Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7 (2001) 3942-3949
    • (2001) Clin Cancer Res , vol.7 , pp. 3942-3949
    • Fidias, P.1    Supko, J.G.2    Martins, R.3    Boral, A.4    Carey, R.5    Grossbard, M.6
  • 13
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3    Mattson, K.4    Gralla, R.5    O'Rourke, M.6
  • 17
    • 31444448873 scopus 로고    scopus 로고
    • Optimizing first-line treatment options for patients with advanced NSCLC
    • Wakelee H., and Belani C.P. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3 (2005) 1-10
    • (2005) Oncologist , vol.10 , Issue.SUPPL. 3 , pp. 1-10
    • Wakelee, H.1    Belani, C.P.2
  • 18
    • 1342268525 scopus 로고    scopus 로고
    • American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
    • Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
    • (2004) J Clin Oncol , vol.22 , pp. 330-353
    • Pfister, D.G.1    Johnson, D.H.2    Azzoli, C.G.3    Sause, W.4    Smith, T.J.5    Baker Jr., S.6
  • 19
    • 23744437871 scopus 로고    scopus 로고
    • Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials
    • Barlesi F., and Pujol J.L. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer 49 (2005) 289-298
    • (2005) Lung Cancer , vol.49 , pp. 289-298
    • Barlesi, F.1    Pujol, J.L.2
  • 20
    • 33144474858 scopus 로고    scopus 로고
    • Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? a meta-analysis of phase III randomized trials
    • Pujol J.L., Barlesi F., and Daures J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? a meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
    • (2006) Lung Cancer , vol.51 , pp. 335-345
    • Pujol, J.L.1    Barlesi, F.2    Daures, J.P.3
  • 21
    • 33750368586 scopus 로고    scopus 로고
    • A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients
    • De Pas T., Putzu C., Curigliano G., Noberasco C., Sabrina B., Catania C., et al. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer 54 (2006) 359-364
    • (2006) Lung Cancer , vol.54 , pp. 359-364
    • De Pas, T.1    Putzu, C.2    Curigliano, G.3    Noberasco, C.4    Sabrina, B.5    Catania, C.6
  • 22
    • 0036729263 scopus 로고    scopus 로고
    • Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial
    • Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
    • (2002) J Clin Oncol , vol.20 , pp. 3578-3585
    • Kosmidis, P.1    Mylonakis, N.2    Nicolaides, C.3    Kalophonos, C.4    Samantas, E.5    Boukovinas, J.6
  • 23
    • 0346560025 scopus 로고    scopus 로고
    • Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975
    • Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
    • (2003) J Clin Oncol , vol.21 , pp. 3909-3917
    • Smit, E.F.1    van Meerbeeck, J.P.2    Lianes, P.3    Debruyne, C.4    Legrand, C.5    Schramel, F.6
  • 24
    • 0017705147 scopus 로고
    • Tumor size, sensitivity to therapy, and design of treatment schedules
    • Norton L., and Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61 (1977) 1307-1317
    • (1977) Cancer Treat Rep , vol.61 , pp. 1307-1317
    • Norton, L.1    Simon, R.2
  • 25
    • 0022504529 scopus 로고
    • Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy
    • Day R.S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46 (1986) 3876-3885
    • (1986) Cancer Res , vol.46 , pp. 3876-3885
    • Day, R.S.1
  • 26
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
    • The TAX 320 Non-Small Cell Lung Cancer Study Group
    • Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al., The TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 12 (2000) 2354-2362
    • (2000) J Clin Oncol , vol.18 , Issue.12 , pp. 2354-2362
    • Fossella, F.V.1    DeVore, R.2    Kerr, R.N.3    Crawford, J.4    Natale, R.R.5    Dunphy, F.6
  • 27
    • 0000619302 scopus 로고    scopus 로고
    • Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma
    • Edelman M.J., and Gandara D.R. Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma. Clin Lung Cancer 1 (1999) 122-127
    • (1999) Clin Lung Cancer , vol.1 , pp. 122-127
    • Edelman, M.J.1    Gandara, D.R.2
  • 28
    • 0035144916 scopus 로고    scopus 로고
    • Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine
    • De Pas T., de Braud F., Mandala M., Curigliano G., Catania C., Ferretti G., et al. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 31 2-3 (2001) 267-270
    • (2001) Lung Cancer , vol.31 , Issue.2-3 , pp. 267-270
    • De Pas, T.1    de Braud, F.2    Mandala, M.3    Curigliano, G.4    Catania, C.5    Ferretti, G.6
  • 29
    • 33744794305 scopus 로고    scopus 로고
    • Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study
    • Lung Cancer Committee of the Hellenic Oncology Research Group
    • Makrantonakis P., Ziotopoulos P., Agelidou A., Polyzos A., Ziras A., Chandrinos V., et al., Lung Cancer Committee of the Hellenic Oncology Research Group. Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Lung Cancer 53 1 (2006) 85-90
    • (2006) Lung Cancer , vol.53 , Issue.1 , pp. 85-90
    • Makrantonakis, P.1    Ziotopoulos, P.2    Agelidou, A.3    Polyzos, A.4    Ziras, A.5    Chandrinos, V.6
  • 30
    • 0035195450 scopus 로고    scopus 로고
    • Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer A multicenter phase II study
    • Agelaki S., Bania H., Kouroussis C., Blazoyiannakis G., Souglakos J., Tsiafaki X., et al. Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer A multicenter phase II study. Lung Cancer 34 Suppl 4 (2001) S77-S80
    • (2001) Lung Cancer , vol.34 , Issue.SUPPL. 4
    • Agelaki, S.1    Bania, H.2    Kouroussis, C.3    Blazoyiannakis, G.4    Souglakos, J.5    Tsiafaki, X.6
  • 31
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Rodrigues Pereira, J.4    Ciuleanu, T.5    von Pawel, J.6
  • 32
    • 34248385777 scopus 로고    scopus 로고
    • Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study
    • Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1 (2006) 847-855
    • (2006) J Thorac Oncol , vol.1 , pp. 847-855
    • Chang, A.1    Parikh, P.2    Thongprasert, S.3    Tan, E.H.4    Perng, R.P.5    Ganzon, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.